Robaxin and Anaemia - a phase IV clinical study of FDA data

Summary:

Anaemia is reported as a side effect among people who take Robaxin (methocarbamol), especially for people who are female, 50-59 old, have been taking the drug for 2 - 5 years also take Zometa, and have Metastases to bone.

The phase IV clinical study analyzes which people have Anaemia when taking Robaxin. It is created by eHealthMe based on reports of 8,252 people who have side effects when taking Robaxin from the FDA, and is updated regularly.

What is Robaxin?

Robaxin has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 9,109 Robaxin users. Check the latest studies of Robaxin.

What is Anaemia?

Anaemia (lack of blood) is found to be associated with 3,032 drugs and 3,943 conditions by eHealthMe. Check the latest studies of Anaemia.

On Jul, 31, 2026

8,252 people reported to have side effects when taking Robaxin.
Among them, 220 people (2.67%) have Anaemia.

Among these 220 people:

* Approximation only. Some reports may have incomplete information.

Do you take Robaxin and have Anaemia?

- Check whether Anaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Robaxin:

Robaxin (9,109 reports)

Anaemia treatments and more:

Anaemia (269,298 reports)

How severe was Anaemia and when was it recovered:

Anaemia in Robaxin

Expand to all the drugs that have ingredients of methocarbamol:

Anaemia and drugs with ingredients of methocarbamol (474 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Robaxin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Anaemia:

Anaemia (3,032 drugs)

Browse all the conditions that are associated with Anaemia:

Anaemia (3,943 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on methocarbamol (the active ingredients of Robaxin) and Robaxin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.